Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) EBIT (2023 - 2025)

Historic EBIT for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$10.0 million.

  • Mereo BioPharma's EBIT fell 684.95% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.0 million, marking a year-over-year decrease of 1982.91%. This contributed to the annual value of -$47.4 million for FY2024, which is 6668.07% down from last year.
  • Mereo BioPharma's EBIT amounted to -$10.0 million in Q3 2025, which was down 684.95% from -$10.5 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year EBIT high stood at -$811000.0 for Q2 2023, and its period low was -$15.3 million during Q4 2024.
  • Its 3-year average for EBIT is -$9.8 million, with a median of -$10.0 million in 2025.
  • Per our database at Business Quant, Mereo BioPharma's EBIT plummeted by 148002.47% in 2024 and then surged by 1806.62% in 2025.
  • Over the past 3 years, Mereo BioPharma's EBIT (Quarter) stood at -$7.1 million in 2023, then crashed by 114.3% to -$15.3 million in 2024, then skyrocketed by 34.44% to -$10.0 million in 2025.
  • Its EBIT stands at -$10.0 million for Q3 2025, versus -$10.5 million for Q2 2025 and -$11.2 million for Q1 2025.